GlassScriptPhysician profile
Rachel Warburton
NPI 1083133300
$3,825.97
in general payments reported to CMS, 2019-2025
20 companies · $3,632 in 2025
The $3,632 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64.73 · 2023: $14.16 · 2024: $115 · 2025: $3,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,761.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $752.37 | 2025 | |
| Madrigal Pharmaceuticals | $387.98 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $383.76 | 2025 | Iqirvo, Bylvay |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $321.99 | 2024-2025 | Xifaxan, Plenvu |
| Janssen Scientific Affairs, LLC | $291.07 | 2025 | Tremfya |
| Lilly USA, LLC | $273.88 | 2025 | Omvoh |
| Genzyme Corporation | $200.08 | 2024-2025 | |
| Pfizer INC. | $188.39 | 2023-2025 | |
| Novo Nordisk INC | $172.82 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $152.00 | 2025 | Entyvio, Gattex |
| Regeneron Healthcare Solutions, INC. | $150.16 | 2024-2025 | Dupixent |
| Janssen Biotech, INC. | $128.88 | 2024-2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $108.94 | 2024-2025 | |
| Ardelyx, INC. | $69.09 | 2025 | Ibsrela |
| Genentech USA, INC. | $64.73 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $62.72 | 2025 | |
| Gilead Sciences, INC. | $42.62 | 2025 | Livdelzi |
| Phathom Pharmaceuticals, INC. | $38.90 | 2025 | Voquezna |
| Evoke Pharma, INC. | $21.99 | 2025 | |
| Aimmune Therapeutics, INC. | $13.60 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Warburton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.